-+ 0.00%
-+ 0.00%
-+ 0.00%

ARRIVENT ANNOUNCES FIRST PATIENT DOSED IN GLOBAL PIVOTAL PHASE 3 ALPACCA TRIAL EVALUATING FIRMONERTINIB FOR FIRST-LINE TREATMENT OF EGFR PACC MUTANT NON-SMALL CELL LUNG CANCER

Reuters·12/22/2025 13:00:02

Please log in to view news